23:41 , Sep 12, 2018 |  BC Extra  |  Politics & Policy

China biopharma stocks fall after centralized tendering talks

Stocks of Chinese biopharma companies slid on Wednesday, possibly in response to a meeting Tuesday of China's National Medical Insurance Bureau on the centralized procurement of generics. Under centralized procurement, a single generic manufacturer would...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:20 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

FDA accepts NDA for Kitov's KIT-302 to treat OA pain and hypertension

FDA accepted for review an NDA from Kitov Pharmaceuticals Holdings Ltd. (Tel Aviv:KTOV; NASDAQ:KTOV) for celecoxib/amlodipine besylate (KIT-302) to treat pain associated with osteoarthritis and hypertension simultaneously. The PDUFA date is May 31. The candidate is...
21:20 , Nov 22, 2017 |  BC Extra  |  Clinical News

Researchers use RWE to reproduce trial results

In an article published in the Journal of the American Medical Association, a team of Harvard researchers used real-world evidence from a U.S. health insurance database to replicate the results of a randomized clinical trial...
16:26 , Mar 17, 2017 |  BC Week In Review  |  Company News

Kitov, Kuhnil deal

Kitov granted Kuhnil exclusive South Korean rights to develop and commercialize KIT-302. Kitov is eligible for undisclosed regulatory milestones and double-digit royalties. Kuhnil will be responsible for obtaining regulatory approval in South Korea and expects...
23:08 , Jan 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; pancreatic cancer Patient sample and mouse studies suggest inhibiting CACNA1D or CACNA1S could help treat invasive breast and pancreatic cancers. In patients with invasive breast cancer, levels of CACNA1D were higher in tumors...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

Celecoxib/amlodipine besylate: Additional Phase III data

Additional data from a double-blind, placebo-controlled, U.K. Phase III trial in 152 patients with hypertension showed that once-daily oral 200 mg celecoxib/10 mg amlodipine besylate for 2 weeks reduced serum creatinine levels by 3.22 umol/L...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Company News

Epic Pharma, Humanwell Healthcare Group, PuraCap Pharmaceutical LLC deal

Humanwell and PuraCap will acquire generic company Epic for $550 million. Epic’s assets include generics of cardiovascular drug amlodipine, marketed as Norvasc by Pfizer Inc. (NYSE:PFE, New York, N.Y.); depression drug citalopram, marketed...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...